Corcept Therapeutics Q1 2023 Earnings Report

Corcept Therapeutics EPS Results

• Actual EPS: $0.14
• Consensus EPS: $0.20
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: $0.20

Corcept Therapeutics Revenue Results

• Actual Revenue: $105.70 million
• Expected Revenue: $104.91 million
• Beat/Miss: Beat by +$790.00 thousand
• YoY Revenue Growth: +12.80%

Corcept Therapeutics Announcement Details

• Quarter: Q1 2023
• Date: 5/3/2023
• Time: After Market Closes

Corcept Therapeutics (NASDAQ:CORT) engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.